Kura Oncology (KURA) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Kura Oncology (KURA) has outperformed Zevra Therapeutics (ZVRA) over the past year, losing 7.7% versus a loss of 8.0%. Over five years, ZVRA leads with a -1.5% price change compared with -48.3% for KURA. Kura Oncology is the larger company by market cap ($807.8 million vs $590.3 million), about 1.4 times the size, while Zevra Therapeutics is growing revenue faster (+350.9% vs +25.2%).
Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus -412.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | ZVRA |
|---|---|---|
| Share price | $9.08 | $9.94 |
| Market cap | $807.76M | $590.27M |
| 1-day change | -6.39% | -3.21% |
| YTD return | -12.61% | +10.94% |
| 1-year return | -7.72% | -8.01% |
| 5-year return | -48.29% | -1.49% |
| P/E ratio (TTM) | — | 10.80 |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $-3.37 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.48M | $106.47M |
| Revenue growth (YoY) | +25.24% | +350.91% |
| Net income (latest FY) | $-278.67M | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | -449.94% | -59.12% |
| Net margin | -412.95% | 78.17% |
| 52-week high | $13.90 | $15.04 |
| 52-week low | $7.36 | $8.01 |
| Distance from 52-week high | -34.68% | -33.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +250.77% | +151.51% |
| Average volume | 1.82M | 1.07M |
| Shares outstanding | 88.96M | 59.38M |
| Employees | 260 | 61 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus -412.9 cents for Kura Oncology.
- Zevra Therapeutics grew revenue faster in its latest fiscal year (+350.91% vs +25.24%).
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Healthcare · Biotechnology · 260 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Healthcare · Biotechnology · 61 employees
KURA vs ZVRA FAQ
Which is bigger, Kura Oncology or Zevra Therapeutics?
Kura Oncology (KURA) is larger, with a market capitalization of $807.76M compared with $590.27M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, KURA or ZVRA?
KURA returned -7.72% over the past 12 months, compared with -8.01% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Kura Oncology and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.